Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue...

Area of Science:

• Oncology
• Medical Oncology
• Clinical Trials

Background:

• Metastatic leiomyosarcomas (uterine or soft-tissue) have a poor prognosis and limited chemosensitivity.
• Trabectedin has demonstrated efficacy in pre-treated leiomyosarcoma patients.
• The LMS-02 trial investigated the combination of doxorubicin and trabectedin as a first-line therapy.

Purpose of the Study:

• To evaluate the efficacy of first-line doxorubicin and trabectedin combination therapy.
• To assess disease control and survival rates in patients with metastatic uterine or soft-tissue leiomyosarcoma.
• To determine the safety and tolerability of this combination regimen.

Main Methods:

• A single-group, multicenter, phase 2 trial (LMS-02) enrolled 109 adult patients with measurable metastatic or unresectable leiomyosarcoma.
• Patients received intravenous doxorubicin (60 mg/m²) followed by trabectedin (1.1 mg/m²) every 3 weeks for up to six cycles.
• The primary endpoint was disease control rate (complete response, partial response, or stable disease).

Main Results:

• Disease control was achieved in 87.2% of uterine leiomyosarcoma patients and 91.8% of soft-tissue leiomyosarcoma patients.
• Partial responses were observed in 59.6% of uterine and 36.1% of soft-tissue leiomyosarcoma patients.
• Common grade 3-4 adverse events included neutropenia (78%), elevated ALT (39%), and thrombocytopenia (37%).

Conclusions:

• Doxorubicin plus trabectedin demonstrates significant activity as a first-line treatment for uterine and soft-tissue leiomyosarcoma.
• The combination therapy shows manageable toxicity, supporting its further development.
• A phase 3 trial comparing this regimen to the current standard of care is warranted.